Pharmacologic management of spasticity in multiple sclerosis

Spasticity is very common in people with multiple sclerosis (MS). It is estimated that between 40 and 60% of all patients are affected. It consists of an abnormal, velocity-dependent increase in the phasic and tonic stretch reflexes, due to an abnormal integration of the nervous system motor responses to sensory input. The cause of spasticity could be due to an interruption of the neural network controlling the muscle stretch reflex in the central nervous system (CNS). Correct management of spasticity is essential and it must start with the identification of achievable goals. Therapeutical approaches include skilled rehabilitation strategies, pharmaceutical agents and surgery. The main objective of the treatment should be minimising the negative impact of the spasticity on disability and quality of life (QoL) of each patient